LIVE — April 23, 10:30PM – MODELING & ANALYTICS @Cambridge HealthTech Institute’s 14th Annual Meeting BioIT World – Conference & Expo ’15, April 21 – 23, 2015 @Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
Dr. Aviva Lev-Ari will be in attendance on April 21, 22, 23
Leaders in Pharmaceutical Business Intelligence (LPBI) are Covering the Event in REALTIME using Social Media
http://pharmaceuticalintelligence.com
#biotech
#investment
@MassBio
@BostonBizJournl
@BioWorld
@BiotechNews
@bioitworld
MODELING & ANALYTICS
April 23, 10:30 Chairperson’s Remarks
Yuriy Gankin, Ph.D., Chief Life Science Officer, EPAM Systems
10:40 Translational R&D Analytics: Delivering ‘Big Insights’ to Drive Translational Research
Kaushal Desai, Associate Director, Translational R&D Analytics and Decision-Support, Research Informatics & Automation, Bristol-Myers Squibb
The emergence of immunotherapy and a focus on systems approaches has led to an unprecedented surge in translational research opportunities for discovery and development of newer treatment paradigms. Organizations leading the race for scientific breakthroughs in patient treatment have accumulated overwhelming quantities of efficacy, survival, safety and biomarker data from decades of preclinical studies and clinical trials. Translational R&D organizations face the arduous task of mining this data to deliver insights that drive translational research. This session will explore case studies demonstrating how translational R&D analytics can inform patient stratification and trial design in early clinical and translational research. The talk will focus on the journey from a lack of discoverability for disjointed datasets to insights that drive key decisions in translational research. Challenges associated with delivering actionable information at the point of decision-making will be highlighted and opportunities to deliver business value will be outlined using real examples from multiple disease areas.
11:10 Integrated Genomics Platform: Putting Patients and Their Genomes into the Focus of Our Research
Nora Manstein, Ph.D., IT Project Manager, Bayer Business Services GmbH
The fast progress in the generation of genomic data has reached the patient. Especially the advent of next generation sequencing and high resolution microarrays enable accurate descriptions of diseases with a strong genetic component ultimately leading to novel therapeutic approaches. Application of these technologies, however, leads to large amounts of data in need of effective storage and analysis. As now several data types (mutation, expression, microRNAs) become available for each patient, patient-centric views and analyses become mandatory. Consistent data handling and storage is a scientific and technological challenge towards both the research organization and the IT infrastructure. We have established the Integrated Genomics Platform (IGP) as a central tool for genomics research in Cardiology, Oncology and Clinical Sciences. The platform supports advanced data analysis and is intended to simplify discovery processes, e.g. for novel therapeutic targets and genetic biomarkers. In this strategic project, we have overcome known bottlenecks and enabled true translational research by establishing a company-wide mandatory repository and toolbox for storage and analysis of genomics data as well as common standards for data annotation, privacy & security.
11:40 Building a Globally Distributed, Hybrid NGS Sequence Analysis and Integration Infrastructure for Oncology Discovery and Translational R&D
Justin H. Johnson, Principal Scientist, AstraZeneca
Next-Generation Sequencing is changing the way pharmaceutical companies develop drugs, perform patient stratification, and evaluate treatment efficacy. However, managing the massive amounts of NGS data has introduced fundamental IT challenges. Here we discuss the implementation of a fast, flexible, scalable and validated IT infrastructure that can streamline the upkeep of the NGS analysis workflow and the distribution of genomic information throughout an organization for translational discovery.
Translational Oncology @AstraZeneca
- Disease biology
- Patient selection
- Diagnostics
- EGFR mutations and NSCLC 60% have One single mutation
- NGS allow identification of new mutation of circulating tumor DNA – progression plasma samples
- Plasma Circulating Tumor DNA ctDNA Sequencing
- NGS is CHanging – Drug development in Oncology
- AZ Production Informatics Mission Statement
- Patient Selection
INFRASTRUCTURE
- Liquid biopsy
- EXOME Seq 16 hrs to 45 min
- WGS 72 hrs to 6 hors
- CLOUD
- FAst and FLexibile
VENDORS; Bina, GMS vs AGXP, NIST, GIAB, Clarity, GetRM, Platinum Genomes
ICGC-TCGA DREAM Somatic Mutation Calling Challenge
- AZ & Bina — AZ Active in BRCA Challenge
Reference Standard – SNP focus
- SOmatic Calls – Horizon DIagnostics
- Assay Performance
- VarDict Key Features
- COmplex Variants
- handles 1M depth wihtout down-sampling
- make accurate composite haplotype calls
- accessing EGFR sequence at Exon 19 in a trial patient
- ansumble approach to identify false positives
- Variants and covered Profiles
- Bina helped to make Bioinformatics to the Biologist Scientists
- Open SOurce Framework for Data Analysis
- Translational NoSQL MongoDB variant warehouse and API
Easy tio Use Modules and GUI
Bina AAiM
BinaRAVE
12:10 pm Session Break
12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing
Leave a Reply